OVCH2 Activators
OVCH2 can be understood through the lens of their interaction with cellular signaling pathways that ultimately lead to the protein's activation via phosphorylation. Forskolin is one such activator that directly stimulates adenylyl cyclase, leading to an increased level of cyclic AMP (cAMP) within the cell. This escalation in cAMP level triggers the activation of protein kinase A (PKA), a kinase that can phosphorylate OVCH2. Similarly, Isoproterenol, a synthetic catecholamine, also elevates cAMP production by activating beta-adrenergic receptors, thereby promoting PKA activation that can target OVCH2. Additionally, prostaglandin E2 (PGE2) operates through its receptors to increase cAMP within the cell, activating PKA which in turn can phosphorylate OVCH2.
Other chemicals that facilitate the activation of OVCH2 function by modulating cAMP levels include IBMX and Vardenafil. IBMX acts as a non-selective inhibitor of phosphodiesterases, thus preventing the degradation of cAMP and indirectly maintaining PKA in an active state that can phosphorylate OVCH2. Vardenafil, by selectively inhibiting phosphodiesterase-5 (PDE5), leads to a tissue-specific increase in cAMP which also enables PKA to phosphorylate OVCH2. Similar in function to Vardenafil, Sildenafil increases cAMP levels in specific tissues, thereby activating PKA which can then act on OVCH2. Anagrelide and Milrinone both inhibit phosphodiesterase 3 (PDE3), causing an increase in cAMP levels and subsequent PKA activation, which can phosphorylate OVCH2. Beta-adrenergic agonists such as Terbutaline, Dobutamine, Albuterol, and Salbutamol raise intracellular cAMP levels, leading to PKA-mediated phosphorylation of OVCH2. PDE inhibitors like Rolipram and Zaprinast specifically target PDE4 and PDE5, respectively, causing an increase in cAMP and activating PKA which can phosphorylate OVCH2. Fenoldopam, a dopamine D1 receptor agonist, and Glucagon, through its receptor, both increase cAMP production, thereby activating PKA and potentially leading to the phosphorylation of OVCH2. Finally, BRL-50481, a selective inhibitor of PDE7, increases cAMP levels within the cell, leading to PKA activation and subsequent phosphorylation of OVCH2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine that activates beta-adrenergic receptors, leading to increased cAMP production via adenylyl cyclase activation. The resulting activation of PKA could phosphorylate OVCH2, leading to its activation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) binds to its G protein-coupled receptors (GPCRs), causing an increase in intracellular cAMP. This, in turn, activates PKA, which could phosphorylate and activate OVCH2. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. By preventing cAMP degradation, IBMX indirectly increases PKA activity, which may lead to the phosphorylation and activation of OVCH2. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil is a selective inhibitor of phosphodiesterase-5 (PDE5), which specifically increases cAMP in certain cell types. This elevation could enhance PKA-mediated phosphorylation of OVCH2, leading to its activation. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase 3 (PDE3), which increases cAMP levels and subsequently activates PKA. Activation of PKA could lead to | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline, a beta2-adrenergic agonist, leads to increased cAMP production via adenylyl cyclase activation. The increase in cAMP levels promotes PKA activity, which could phosphorylate and activate OVCH2. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, leading to increased cAMP levels in the cell. Elevated cAMP activates PKA, which might then phosphorylate and activate OVCH2. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast selectively inhibits PDE5, which results in increased cAMP levels. The cAMP activates PKA, and the PKA could phosphorylate OVCH2, leading to its activation. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine is a beta1-adrenergic agonist. Its activation of beta1 receptors leads to increased cAMP and PKA activation, which could in turn phosphorylate and activate OVCH2. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Albuterol, a beta2-adrenergic receptor agonist, increases intracellular cAMP levels, leading to PKA activation. PKA then has the potential to phosphorylate and activate OVCH2. | ||||||